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Abstract
Background: Measurements of Energy Expenditure (EE) at rest (REE) and during physical activities are increasing in interest
in chronic patients. In this study we aimed at evaluating the validity/reliability of the SenseWearHArmband (SWA) device in
terms of REE and EE during assisted walking in Chronic Respiratory Failure (CRF) patients receiving long-term oxygen
therapy (LTOT).
Methodology/Principal Findings: In a two-phase prospective protocol we studied 40 severe patients and 35 age-matched
healthy controls. In phase-1 we determined the validity and repeatability of REE measured by SWA (REEa) in comparison
with standard calorimetry (REEc). In phase-2 we then assessed EE and Metabolic Equivalents-METs by SWA during the 6-
minute walking test while breathing oxygen in both assisted (Aid) or unassisted (No-Aid) modalities. When compared with
REEc, REEa was slightly lower in patients (13516169 vs 14136194 kcal/day respectively, p,0.05), and less repeatable than
in healthy controls (0.14 and 0.43 coefficient respectively). COPD patients with CRF patients reported a significant gain with
Aid as compared with No-Aid modality in terms of meters walked, perceived symptoms and EE.
Conclusions/Significance: SWA provides a feasible and valid method to assess the energy expenditure in CRF patients on
LTOT, and it shows that aided walking results in a substantial energy saving in this population.
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Introduction
Among new methods to objectively assess Energy Expenditure
(EE) both at rest (REE) or during activity, the SenseWearHArm-
band (SWA) device has been validated in healthy normal-weight
[1–5] or obese [6] individuals and in chronic patients with heart
failure [7] or diabetes [8].
This is a multisensor device easily applied and carried by
humans that allows to continuously measure active movements
and to derive energy expenditure throughout; a specific software is
associated for this calculation.EE measurement by SWA has been
shown to have elevated reliability during standard walked distance
(6MWT) even in patients with chronic obstructive pulmonary
disease (COPD) [9–10]. However, it is not yet proved that SWA is
also feasible to assess EE during walking in those COPD patients
suffering from Chronic Respiratory Failure (CRF) and requiring
long-term oxygen therapy (LTOT).
These patients generally suffer from progressive physical
disability and muscles de-conditioning which often cause restric-
tion in daily activities (such as self-directed walking) [11]. In this
population, a walking aid to carry oxygen canister can help to
improve exercise performance and related symptoms [12];
notwithstanding, it is not known whether this improvement is
also favourable in terms of EE.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information: see Figure 1.
Objectives
In the present study we aimed at evaluating both 1) the validity
of the SWA device and its reliability in terms of resting energy
expenditure (REE), and 2) the effect of a walking aid in terms of
EE to carry the oxygen canister in COPD patients with CRF.
Patients and Controls
Consecutive patients fulfilling criteria for LTOT for at least 6
months and admitted to our rehabilitation center in the period
January–December 2008 were screened. Among all of them, those
without COPD and who reported any significant and clinically
evident concomitant cardiovascular or metabolic disease were
excluded. In addition, COPD with neuro-motorial diseases and/or
cognitive failure unable to perform 6MWT were also excluded.
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Diagnosis and staging of COPD was made according to the
GOLD definition and classification [13].
Healthy individuals matched by age, sex and body mass were
selected in the same period and served as the control population.
Those individuals reporting cardiovascular or metabolic disease,
with a smoking history .5 pack/year, and/or with alterations at
the spirometry were excluded. For details see Figure 1.
Study protocol
This was a prospective two-phase study to compare data
obtained in similar condition from both CRF patients and
controls.
In phase-1 we determined the validity of REE (calculated also by
body weight-W correction) measured by SWA (REEa) in
comparison with standard calorimetry (REEc). Measurements
were taken on the study day in the morning while breathing room
air in both groups.
In phase-2 we then assessed EE and Metabolic Equivalents-
METs by SWA in both groups during 6MWT performed in both
modalities while breathing oxygen with a trolley carried on the
dominant shoulder (No-Aid) or pulled on a wheeled cart (Aid) as
previously described [12]. The weight of the oxygen trolley
(3,5 kg) and the flow of oxygen administration during walking test
were the same (3 litres/min) in both modalities and in the two
study groups. The controls repeated the experiments while
breathing room-air on a subsequent day.
The two walking modalities were conducted in random order
on a same day (2 hour apart) and after achieving a complete
recovery to baseline (dyspnoea and symptoms) in between. The
same respiratory therapist unaware of the study purposes assisted
all the tests.
Measurements
General data. Demographic and anthropometric data were
described in all the participants.
Body measures were collected by the same dietician and
according to the Anthropometric Standardization Reference
Manual [14] and the Italian Dietician National Association
(ANDID) [15]. Body mass index (BMI) was calculated by dividing
body weight (kg) for the squared height in meters (kg/m2). Body
circumferences, obtained through a flexible and inextensible string
at the level of both upper middle arm, waist and hip, were
expressed in centimetres (cm). A mechanic plicometer (John Bull,
British Indicators LTD) with standardized-pressure calibre was
used at the level of triceps, biceps, under-scapular and up-iliac
plica. A body bio-impedenziometric analyzer (Tanita Corporation
BC-420MA) was used to assess body composition, respectively as
fat (FMI) and fat free mass (FFMI) indexes and both expressed as
kg/m2 [16].
Lung volumes (FEV1, FVC and FEV1/FVC) by means of a
spirometer (Masterscope; Jaeger; Hoechberg, Germany) were
expressed as absolute or percentage of predicted values [17]. Blood
sample for the measurement of pH, PaO2, PaCO2, and PaO2/
FiO2 ratio (Model 850; Chiron Diagnostics; Medfield, MA) was
taken from the radial artery of CRF patients while in the sitting
position and at rest.
Figure 1. Study flow diagram.
doi:10.1371/journal.pone.0023770.g001
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The 6MWT was performed according to guidelines [18]. A pre-
test evaluation, while wearing SWA, was executed in all the
participants to limit the possible learning effect [19]. Patients
showing .5% variation of EE recording by SWA during two pre-
test 6MWT were not considered; the best of other two consecutive
walked distance test was then selected for recording measures in
the patients selected.
The total distance walked was calculated as absolute and
percentage of predicted (% pred.) values in meters [20]. Oxygen
saturation (SatO2) and maximal heart rate (HR max) were
continuously monitored throughout the test by means of a
pulsoximeter (Pulsox 3; Minolta; Tokyo, Japan). Baseline SatO2
(SaO2 pre-test), mean and minimal values of oxygen saturation
(DeSaO2 and SaO2-nadir, respectively), rate of dyspnoea and
muscle fatigue by modified Borg 10-points scale [21] at the
beginning and the end of 6MWT, were also recorded.
Energy expenditure evaluation at rest and during walking
test. The REEc and REEa recordings were obtained by the
contemporary application of indirect calorimeter (Sensormedics
VMAX Spectra 29N with canopy) and SWA (Pro2 ArmbandH,
Body Media Inc, Pittsburgh, PA, USA) respectively. Tests were
made at the same time in the morning, with empty stomach (at
least 12 hours) and free from any type of strenuous physical
activities for at least 24 hours [22].
In a room with fixed temperature between 70 and 75uF, the
SWA was worn on the upper right arm of the participants while in
orthostatic position at rest; this procedure was necessary for sensor
skin temperature acclimatization. Pushing the button (timestamp)
on SWA it was possible to identify exactly the periods of test’s
beginning-end (twenty minutes). The recorded period was
multiplied by the value of 3 (determination of the REEa in one
hour, kcal/h) and thereafter by 24 (REEa in a day, kcal/day) [23].
A software device (InnerViewH Research Software, Professional
version 6.1, USA) was then used for accurate reading and referring
values.
During the indirect calorimetry test, oxygen-consumption (VO2)
and volume of carbon dioxide (VCO2) were used in order to
calculate the REEc in agreement with the formula of Weir [24].
The acceptability criteria of recordings as obtained from this test
was a variation ,5% in the respiratory-quotient/minute and
VO2/min with at least 15 minutes of steady state.
Measurements during walking test were taken by SWA worn on
the right upper arm and activated at least 10 minutes before
starting the test: the timestamp signed exactly both beginning and
end of walking time. Measures of change in EE and METs .5%
obtained at 6MWT (pre-test and test) were excluded from data
collection. Recordings of EE and METs were then normalized by
walked meters ratio (EE/6MWT, kcal/mt and METs/6MWT,
kcal/kg/h/mt) and used as study outcomes.
Ethics
The Villa Pineta Foundation review board has approved the
study which was conducted according to the Declaration of
Helsinki. Participants gave their written informed consent to be
included. No current external funding source has been assigned.
Statistical analysis
Analysis was made by specific software (SPSS ver. 8.0 and
Analyse-itH software Ltd. for Microsoft Excel standard edition). All
the considered parameters were expressed as mean 6 standard
deviation (SD) and range. A probability value (p),0.05 was
considered as significant of difference for comparison.
The Bland and Altman [25] test was performed in order to
evaluate repeatability and validity between different methods
(VMAX Spectra 29N and SWA). With this analysis, repeatability
can be accepted when no more than 5% of the calculated
differences between values of each variable obtained during the
two successive metabolic measurement exceeding the coefficient of
repeatability, which is taken as twice the standard deviation of the
differences between pairs of repeated observations.
Comparison of variables between groups and walking modal-
ities (No-Aid and Aid) was carried out by t-test of Student and two
ways ANOVA. The Wilcoxon and Kruskal-Wallis tests were also
applied for non parametric variables.
In CRF population a sub-group comparison in patients with
different performance at the 6MWT (, or $300 meters walked)
was also made.
Results
General characteristics of CRF patients and controls are
reported in Table 1. COPD patients were in advanced stage of
the disease with hypoxemia on ambient air at rest (data not
displayed), but corrected with adequate oxygen supplement (mean
need = FiO2 28%) which approximates the severity of their CRF.
All these patients were in GOLD stage IV by definition [13]. BMI
were similar by definition between groups, although body
circumferences and FFMI in male (1762 and 1961 kg/m2,
respectively) were lower in patients than in controls.
Phase-1
Whole comparison of REEc and REEa in the study groups is
shown in Figure 2. As expected, mean data were higher in CRF
with a significant difference for REEc only (1413 vs 1258 kcal/day,
in patients and controls, respectively). Similar findings were shown
by analysis of REE and W ratio (REE/W).
SWA assessment significantly underestimated REEa when
compared with standard REEc in CRF but not in healthy
population. The Bland and Altman analysis between the two
methods (Figure 3) has shown a greater repeatability grade in
controls than in CRF patients (0.43 and 0.14, respectively).
Phase-2
Table 2 summarizes results of the 6MWT as obtained in the two
groups and comparing both modalities of assisted (Aid) and
unassisted (No-Aid) walking. Exercise performance in both modal-
ities was lower in CRF patients when compared with healthy
individuals. However, at difference with controls, CRF experienced
a significant improvement with Aid as compared with No-Aid in
terms of meters walked (+23,5 m) and perceived symptoms (20,86
and 20,95 at the Borg dyspnea and leg fatigue, respectively).
Metabolic data as obtained in the two study groups during
walking tests (EE/6MWT and METs/6MWT) are displayed in
Figure 4. Walking energy expenditure was higher in CRF than in
controls and in both walking modalities. Interestingly, this was
significantly lowered with Aid modality in CRF only (20,19 kcal/
mt at EE/6MWT and 20,003 kcal/kg/h/mt at METs/6MWT).
An opposite behaviour was found in the control situation,
independent on the oxygen breathing.
It is also interesting to note that, when comparing the Aid and
No-Aid modalities, given a similar improvement of meters walked
(mean difference +28634 and +19658 m, respectively-ns) and
symptoms, the magnitude of reduction in walking energy
expenditure with Aid was higher in the sub-group of CRF patients
performing ,300 m (mean difference 20,02860,02 and
20,004160,003 for EE/6MWT and METs/6MWT, respective-
ly-p,0.001) than in those walking $300 m (mean difference
20,01060,01 and 20,001360,001 for EE/6MWT and METs/
Energy Expenditure in Chronic Respiratory Failure
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6MWT, respectively-p,0.05) at baseline 6MWT (data not showed
in table).
Discussion
Present study provides additional information about SWA
device as a feasible and valid instrument to assess energy
expenditure in disabled CRF patients fulfilling the criteria for
and using LTOT. Measurement of EE by means of SWA
demonstrated that assisted walking results in a substantial saving
when compared with conventional walking in this population.
The use of complex methods to assess EE in humans (i.e. radio-
isotopic systems), although theoretically ideal, is rather difficult due
to several technical problems, elevated costs and the inability to
objectively record specific patterns during physical activity. On the
other hand, easy devices like pedometers, although optimally
validated during walking in healthy subjects [26], are not adequate
to assess metabolic data, nor they may be sensible enough in case
of slow body movements, such as the case of the typical walking of
disabled COPD patients [27].
In recent years, multi-axial accelerometers and integrated body-
monitors with skin sensors (such as SWA) have been tested for
their validity and reliability to assess EE in healthy subjects
[28][29], in COPD [30] and in other chronic conditions
[7][8][31].
Validity of SWA, compared with indirect calorimetry as the gold
standard method, has been already and previously demonstrated in
healthy individuals and in patients with extra-pulmonary disorders
[1–8]. In COPD patients, SWA applied during standard 6MWT
demonstrates a metabolic accuracy equivalent to the portable
‘‘breath-to-breath’’ system with a under-estimation of approxi-
mately 1% when the walking speed was ,3 miles/hours [9]. More
recently Hill and coworkers [10] have found a good coefficient of
repeatability with SWA, when compared with indirect calorime-
try, when measuring energy expenditure in a population of COPD
of similar degree of lung obstruction as in our present research, but
without respiratory failure.
In our study, REE level with both methods was considerably
more elevated in CRF patients than in healthy controls, which
clearly stands for the increased metabolism at rest in these patients
[32][33]. However, SWA assessment underestimated REE value
in COPD but not in controls, which confirms previous separate
findings in the same disease [10] and in normal-weight individuals
[1][2].
Table 1. General characteristics of the population in study.
CRF patients
(n =40)
Controls
(n=35) p
Male/Female 26/14 17/18 0.123
Age, years 71.5 (7.3) [59–86] 69.4 (6.1) [60–83] 0.210
BMI, kg/m2 24.1 (4.2) [15.4–36.4] 25.8 (4.0) [19.4–31.6] 0.083
FEV1
L 1.03 (0.3) [0.4–1.7] 2.71 (0.5) [2.0–3.6] ,0.001
% predicted 41.0 (9.6) [16–54] 115.6 (16.8) [87–148] ,0.001
FCV
L 2.10 (0.6) [0.9–3.1] 3.38 (0.8) [2.1–5.0] ,0.001
% predicted 61.9 (12.2) [35–79] 118.7 (19.4) [80–156] ,0.001
FEV1/FCV, % 49.9 (12.0) [28–69] 76.8 (7.4) [69–88] ,0.001
PaO2, mmHg (on oxygen) 69.8 (11.5) [51–76] - -
PaCO2, mmHg (on oxygen) 46.2 (9.2) [31–53] - -
Supplemental oxygen required (FiO2), % 27.8 (3.2) [24–36] - -
PaO2/FiO2 254.3 (52.7) [162–357] - -
Arm circumference, cm 25.9 (2.7) [21–35] 28.4 (3.1) [24–35] 0.009
Waist circumference, cm 84.6 (8.0) [72–99] 97.0 (13.7) [70–125] ,0.001
Hip circumference, cm 88.6 (7.5) [74–101] 99.8 (5.7) [91–111] ,0.001
Tricipital plica, mm 8.8 (3.2) [1.1–14.3] 8.8 (8.8) [1.1–25] 0.635
Bicipital plica, mm 8.7 (7.0) [1.1–25] 8.2 (9.0) [1.1–30] 0.822
Sub-scapular plica, mm 12.3 (6.8) [1.1–25] 17.4 (24.4) [1.1–65] 0.264
Up-iliac plica, mm 14.8 (6.3) [1.1–29] 22.5 (26.5) [1.1–58] 0.115
FMI, kg/m2
Male 6.30 (3.7) [0.9–10.4] 8.26 (2.0) [5.7–11.0] 0.241
Female 9.55 (3.0) [5.6–13.4] 10.04 (4.3) [5.7–20.7] 0.779
FFMI, kg/m2
Male 17.01 (2.1) [13.2–19.8] 19.42 (1.3) [17.5–21.0] 0.022
Female 15.07 (1.6) [13.4–18.1] 16.04 (1.9) [13.6–19.1] 0.258
Value expressed as mean 6 standard deviation (SD) and [range].
FMI: Fat mass index; FFMI: Fat-free mass index.
doi:10.1371/journal.pone.0023770.t001
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This powerlessness of SWA could be linked to the technical
characteristics of the device in data recording. Indeed, skin sensors
of SWA prevent from perceiving both the pulmonary and
respiratory muscle activity quota, which is known to be increased
in CRF patients [34][35]. To confirm the lack of full repeatability
between SWA and indirect calorimetry, the Bland and Altman
coefficient has shown a low degree of repeatability, which was
lower in CRF patients than in controls (see Figure 3) with 2
patients (5% of total) out of the 95% limits of agreement (between
2234 and +338). This result in CRF seems to be worse than the
previous one [10]; however, our patients are least comparable with
those in that study due to their different clinical characteristics and
overall severity mainly related with the use of LTOT, and with the
specific reduction in FFMI (at least in male subjects, as shown in
Table 1) [16][36][37]. Moreover and finally, repeatability
coefficient (0.43) was also lower in our controls when compared
with those in previous study [2]; this aspect is probably linked to
the older age of our individuals thus influencing metabolic
recordings with SWA, to our knowledge not still validated in
elderly population.
In phase-2 of our study we then principally aimed at assessing
EE by SWA during assisted or unassisted walking, in order to
confirm the potential energy saving we have previously hypoth-
esized when using the trolley on a wheeled cart to facilitate
ambulation of CRF on domiciliary oxygen [12]. The usefulness
and reliability of EE assessment by SWA during flat walking has
been recently confirmed in the population of COPD [10].
Present study documented that aided modality of walking
enabled these severe COPD patients to considerably save energy,
which was not the case in the control population. In particular,
due to the weight reduction of the oxygen trolley put on the
shoulder, the aided modality to walk allowed patients to have a
meaningful reduction of energy during the test both in terms of
expenditure (about 20% less) and METs (about 25% less).
Moreover and interestingly, this metabolic together with the
clinical benefit in the Aid modality is much higher in the subgroup
of patients at the lowest grade of exercise performance (,300 m.
at 6MWT, 50% of the our sample).
The practical translation of this finding is that any form of aid
might thus increase physical activity in this very advanced and
disabled population [38][39]. Indeed, improvement of the
metabolic work would parallel the individual’s reserve in heart
rate and oxygen consumption, directly linked with any positive
change in the aerobic activity [38]. Notwithstanding, this result
Figure 2. Comparison of REE and REE/W values obtained by
indirect calorimetry and SWA in the two study groups (for
details see Methods). *p,0.05, **p,0.001, ns: not significant.
doi:10.1371/journal.pone.0023770.g002
Figure 3. Bland & Altman analysis and repeatability coefficients in the two study groups.
doi:10.1371/journal.pone.0023770.g003
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only leads to hypothesize a bio-enzymatic adaptation at the
skeletal muscle level, since our study was not designed as
physiologic.
The lack of positive change with EE and symptoms during
assisted walking in the controls would be more likely related to a
sort of ‘‘obstacle-effect’’ when using the aid device. In this
population, pulling the wheeled cart on the floor translated in
additional work, symptoms and energy expenditure; similar (and
even worse) results were found when breathing room air, thus
excluding the possible bias effect of oxygen inhalation on EE
measurement.
Taking these consideration all together, we conclude that SWA
can be a feasible and valid device to measure and to monitor
energy expenditure in very severe COPD patients with chronic
respiratory failure. In these disabled patients the daily use of
ambulatory oxygen can be helped by a simple and small wheeled
cart with is associated by a better performance, reduced symptoms
and relevant saving in energy consumption, which is more likely to
observe in those patients with lower walking performance
(,300 m at the 6MWT).
Limitations
Even if the SWA device has been validated in healthy and
COPD patients showing to have an elevated reliability during
6MWT, we can’t exclude that the energy saving during a walking
aided may be a reflection of the inability of the SWA to capture
EE when the upper arm is not moving normally, due to the pulling
of the walking aid.
Moreover, one could criticize the choice of 6MWT as the best
test to assess EE in healthy individuals. In general, this is certainly
a test at which work rate is not standardized; however, the
application of clear and standardized instructions during assess-
Table 2. Results of the exercise performance in the population in study.
CRF patients#
(n =40)
Controls#
(n =35)
Controls in room air
(n =35)
No-Aid Aid p No-Aid Aid p No-Aid Aid p
Distance walked at 6MWT, meters 295.2 (90.8) 318.7 (90.0) 0.003 506.2 (50.5) 482.1 (43.6) ,0.001 501.0 (54.4) 484.2 (43.5) 0.002
Distance walked at 6MWT, % predicted 61.4 (17.8) 67.5 (19.0) 0.003 110.9 (14.1) 103.9 (13.8) ,0.001 109.1 (14.9) 105.2 (13.4) ,0.001
Peak effort dyspnoea, Borg{ 4.67 (2.0) 3.81(1.8) ,0.001 1.28 (0.7) 1.51 (0.7) 0.053 1.14 (0.7) 1.48 (0.7) 0.005
Peak leg effort fatigue, Borg{ 3.60 (1.8) 2.65 (1.2) ,0.001 1.40 (0.7) 1.59 (0.7) 0.076 1.31 (0.9) 1.53 (0.7) 0.024
RR at peak effort, breaths/min 22.8 (4.1) 21.6 (3.2) ,0.001 18.7 (1.7) 19.1 (2.0) 0.051 18.7 (2.3) 19.4 (2.2) 0.001
HR max, beats/min 109.2 (9.9) 106.1 (11.5) 0.067 105.4 (9.2) 105.0 (11.4) 0.751 106.5 (10.2) 110.6 (10.7) 0.036
SaO2 pre-test, % 94.1 (2.3) 94.8 (1.8) 0.601 97.4 (1.0) 97.6 (0.8) 0.905 95.6 (1.3) 95.7 (1.3) 0.231
SaO2, % 88.7 (3.3) 89.4 (3.8) 0.060 95.5 (1.1) 95.4 (0.9) 0.497 94.0 (1.1) 93.5 (1.2) 0.001
Reduction of SaO2 during 6MWT, % 5.35 (2.8) 5.36 (3.6) 0.990 1.86 (1.1) 2.24 (1.0) 0.049 1.62 (1.0) 2.20 (1.2) ,0.001
Nadir of SaO2 during 6MWT, % 84.1 (5.9) 85.5 (5.8) 0.019 93.7 (1.5) 93.7 (1.8) 0.926 91.4 (1.9) 91.6 (1.8) 0.546
Value expressed as mean 6 SD.
#Test performed breathing oxygen at 3 L/min.
{Differences calculated using no-parametric test of Kruskal-Wallis and Wilcoxon test.
doi:10.1371/journal.pone.0023770.t002
Figure 4. Comparison of EE outcomes recorded during both assisted (Aid) and unassisted (No-Aid) walking in both CRF patients
(panel A) and Controls (panel B) (for details see Methods). **p,0.001, ns: not significant.
doi:10.1371/journal.pone.0023770.g004
Energy Expenditure in Chronic Respiratory Failure
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23770
ment translates into a likely ability of the individuals to walk at his/
her best intensity, which is known to be reached within 2 minutes
after beginning. Therefore, the standard walking is a widely
accepted and reliable test to assess physical performance even in
normals [40].
Finally, and despite the criteria adopted to select our study
population (see Methods), a substantial number of COPD still
have concomitant cardiovascular and metabolic diseases at least at
a sub-clinical level that might theoretically bias the sample
selection.
Taking the limits and/or advantages of SWA device, it is likely
that future studies will clarify its role as a metabolic holter in
elderly population, in chronic respiratory diseases other than
COPD (i.e. pulmonary fibrosis), and in diseases with skin
involvement (i.e. sclerodermia).
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